Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 202-208

  Morgan, Denis J ^a   Hill, John S ^b   Clarke, Kerrie ^c   Stylli, Stan S ^b   Park, Samantha J ^b   Cebon, Jonathan ^d   Basser, Russell L ^e   Kaye, Andrew H ^b   Geldard, Howard ^f   Maher, Darryl W ^c   Green, Michael D ^b  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d AUSTIN HEALTH   (Australia)

^e Western Hospital   (Australia)

^f IDT Australia Ltd   (Australia)

Author keywords

Antracyclines; MX2; Pharmacodynamics; Pharmacokinetics

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; NEUTROPHIL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CARUBICIN; DOXORUBICIN; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; SAFETY;

EID: 8244243234     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050647     Document Type: Article

References (31)

1. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Runane M, Sinkule JA (1989) Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 45: 340
2. Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071
3. Canal P, Robert J, Ramon M (1992) Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. Clin Pharmacol Ther 51: 249
4. Cosolo WC, Morgan DJ, Seeman E, Zimet AS, McKendrick JJ, Zalcerg JR (1994) Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs 5: 293
5. Desoize B, Robert J (1994) Individual dose adaptation of anticancer drugs. Eur J Cancer 30A: 844-851
6. Egorin MJ, Van Echo DA, Whitacre MY (1986) Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46: 1513
7. Elbaek K, Ebbehoj E, Jacobsen A, Juul P, Rasmussen SN, Bastholt L, Dalmark M, Steiness E (1989) Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumour activity and side effects. Clin Pharmacol Ther 45: 627
8. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin M (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180
9. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
10. Holford NHG, Sheiner LB (1982) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429
11. Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Giedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT (1991) A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood sample measurement. Cancer Chemother Pharmacol 28: 465
12. Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT, Jakobsen A (1991) Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 28: 63
13. Majima H (1989) Phase 1 clinical and pharmacokinetic study of KRN8602 (abstract). Proc Am Soc Clin Oncol 8: 245
14. Majima H, Shinkai H (1991) Pharmacokinetics of KRN8602 in cancer patients. Jpn J Cancer Chemother 18: 2589
15. Marchiset-Leca D, Leca F-R, Galeani A, Catalin J (1995) Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics. Cancer Chemother Pharmacol 36: 239
16. Newell DR (1994) Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy? Ann Oncol 5 [Suppl 4]: S9
17. Piscitelli SC, Rodvold KA, Rushing DA, Tewlsbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53: 555
18. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ (1990) Pharmacodynamics in cancer therapy. J Clin Oncol 8: 1739
19. Reilly JJ, Workman P (1993) Normalisation of anti-cancer drug dosage using body weight and surface area: is it worth-while? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32: 411
20. Reilly JJ, Workman P (1994) Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol 34: 3
21. Robert J, Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467
22. Robert J, Monnier A, Poutignat N, Herait P (1991) A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemother Pharmacol 29: 75-79
23. Sato Y, Eddy L, Hochstein P (1991) Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol 42: 2283
24. Shinkai H, Takahashi H, Kikuchi K, Kawai H, Otake N (1991) Determination of the new morpholino anthracycline MX2-HC1 and its metabolites in biological samples by high performance liquid chromatography. J Chromatogr 570: 203
25. Tabata M, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nagamine D, Shinagawa K, Fukutani H, Hirano A, Mizunuma N, Itami S (1989) Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline. Jpn J Cancer Chemother 16: 2361
26. Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G, Green MD (1990) Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 50: 5095
27. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B (1992) Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29: 391
28. Watanabe M, Komeshima N, Nakajima S, Tsuruo T (1988) MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48: 6653
29. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T (1991) Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Cancer Res 51: 157
30. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39: 1
31. Wolfrom C, Hartmann R, Fengler R, Bruhmuller S, Ingwersen A, Henze G (1993) Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 11: 827